Loading
Led RxPONDER, which showed postmenopausal women with 1-3 positive nodes and low recurrence scores do not need chemotherapy.
Kevin Kalinsky was principal investigator of SWOG S1007 (RxPONDER), which extended the TAILORx result to node-positive disease: postmenopausal women with one to three positive nodes and a recurrence score of 25 or less gained nothing from chemotherapy, while premenopausal women did. He directs breast oncology at Winship and leads SWOG breast trials on ctDNA-guided escalation.
| Title | Journal | Year |
|---|---|---|
| 21-gene assay to inform chemotherapy benefit in node-positive breast cancer (RxPONDER) | NEJM | 2021 |
| Randomized phase II trial of endocrine therapy with or without ribociclib after neoadjuvant chemotherapy in HR-positive breast cancer (NeoPAL and related studies) | Clinical Cancer Research | 2020 |
Shares Oncotype DX, HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares RxPONDER (SWOG S1007), Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares RxPONDER (SWOG S1007), Oncotype DX, HR-positive / HER2-negative breast cancer.
Shares HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.
Shares HR-positive / HER2-negative breast cancer and the tags breast, de-escalation.